Tag Archives: Takeda

Biologics by McKesson and Onco360 Selected as Specialty Pharmacy Partners for Fruzaqla, Ogsiveo, and Truqap

Biologics by McKesson and Onco360 Selected as Specialty Pharmacy Partners for Fruzaqla, Ogsiveo, and Truqap

Takeda Selects Specialty Pharmacy Partners for ADZYNMA and FRUZAQLA

Takeda Pharmaceuticals Selects Specialty Pharmacy Partners for new FDA-approved drugs ADZYNMA and FRUZAQLA

Biologics by McKesson Starting the New Year With Momentum

Biologics by McKesson, selected as a specialty pharmacy distributor for three specialty drugs recently, is starting the new year with momentum

Amber Specialty Pharmacy Selected by Takeda to Dispense LIVTENCITY™

Amber Specialty Pharmacy announced that it will begin dispensing LIVTENCITY™ (maribavir), the first and only treatment indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease

Highmark’s Strategy to Contain Drug Costs Includes an Increasing Number of Outcome-Based Contracts

Pharmaceutical manufacturers and payers have developed a number of agreements under which reimbursement is contingent on specific outcomes over the last few years